Estrella Immunopharma(ESLA)
$0.34+0.01 (+2.41%)
ESLA
Estrella Immunopharma financials statements
$0.34
At close:+0.01 (+2.41%)
Estrella Immunopharma (ESLA) Ratios
48 Followers
Estrella Immunopharma Ratios
ESLA's free cash flow for Q3 2026 was $-217.21K. For the 2026 fiscal year, ESLA's free cash flow was increased by $0.00 and operating cash flow was $-217.21K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Jun 24 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.12 | 0.55 | 24.65 | 0.05 | 5.20 |
| Quick Ratio | 0.12 | 0.55 | 24.65 | 0.05 | 5.20 |
| Cash Ratio | 0.10 | 0.31 | 23.05 | 0.04 | 4.32 |
| Solvency Ratio | -0.96 | -2.95 | -40.46 | -0.26 | -0.24 |
| Operating Cash Flow Ratio | -0.13 | -2.55 | -88.92 | -0.97 | -1.52 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | -2.09 | 0.00 |
| Net Current Asset Value | $ -11.87M | $ -1.36M | $ 4.27M | $ -2.86M | $ -1.04M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.05 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.07 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.07 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.31 | 21.85 | 1.04 | 1.41 | -4.73 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -1.54 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.09 | 0.00 |
| Net Debt to EBITDA | 0.11 | 0.10 | 0.57 | -0.67 | 366.34 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.01% | 100.02% | 100.02% | 108.81% | 100.00% |
| EBT Per EBIT | 100.00% | 100.00% | 100.00% | 58.33% | 100.00% |
| Return on Assets (ROA) | -411.19% | -281.70% | -164.15% | -9.97% | -34.24% |
| Return on Equity (ROE) | 126.02% | -6155.69% | -171.09% | -14.09% | 162.08% |
| Return on Capital Employed (ROCE) | 126.01% | -6154.51% | -171.06% | -17.61% | -42.40% |
| Return on Invested Capital (ROIC) | 126.01% | -6154.51% | -171.06% | -16.68% | -2.95% |
| Return on Tangible Assets | -411.19% | -281.70% | -164.15% | -9.97% | -34.24% |
| Earnings Yield | -22.74% | -20.10% | -18.88% | -1.68% | -2.88% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.05 | -0.21 | -0.46 | -0.18 | -0.25 |
| Free Cash Flow Per Share | -0.05 | -0.21 | -0.46 | -0.18 | -0.25 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -7639673.00 | -4017076.50 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | -7639673.00 | -4017076.50 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | -2.09 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -3.11% | -17.36% | -41.50% | -1.76% | -2.47% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.46 | -4.80 | -5.30 | -59.53 | -34.71 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -5.54 | 306.25 | 9.06 | 8.39 | -56.26 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -32.17 | -5.76 | -2.41 | -56.81 | -40.57 |
| Price-to-Operating Cash Flow Ratio | -32.17 | -5.76 | -2.41 | -56.81 | -40.57 |
| Price-to-Earnings Growth (PEG) Ratio | -0.10 | -0.25 | -0.23 | 1.44 | -0.03 |
| Enterprise Value Multiple | -4.29 | -4.87 | -4.73 | -86.99 | -4875.33 |
| Enterprise Value | 56.06M | 43.10M | 34.56M | 59.76M | 54.41M |
| EV to EBITDA | -4.29 | -4.87 | -4.73 | -86.99 | -4875.33 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -31.39 | -5.64 | -2.15 | -57.25 | -37.73 |
| EV to Operating Cash Flow | -31.39 | -5.64 | -2.15 | -57.25 | -37.73 |
| Tangible Book Value Per Share | -0.28 | 0.00 | 0.12 | 1.23 | -0.18 |
| Shareholders’ Equity Per Share | -0.28 | 0.00 | 0.12 | 1.23 | -0.18 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.09 | 0.14 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.35 | -0.24 | -0.21 | -0.17 | -0.29 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.09 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 6.80 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.14 | 0.86 | 2.20 | 1.05 | 0.86 |
Currency in USD

